Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Want to cut your energy bills? Here’s how five experts are doing it 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
SEATTLE, Feb. 27, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017, at 3:20 p.m. Eastern time / 12:20 p.m. Pacific time in Boston.
A live audio webcast of the presentation will be available through the “Events & Presentations” page of the “News & Events” section of Cascadian Therapeutics’ website at cascadianrx.com. An archived edition of the session will be available later that day.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib (also known as ONT-380) is an oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.
Investor and Media Contact: Monique Greer Cascadian Therapeutics 206-801-2107 [email protected]
